Summit Therapeutics PLC (FRA:UVF1)
€ 0.2 0 (0%) Market Cap: 65.72 Mil Enterprise Value: -366.07 Mil PE Ratio: 0 PB Ratio: 31.60 GF Score: 14/100

Summit Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 09:30PM GMT
Dan Delfico J.P. Morgan;Co.;Moderator

&-

Good afternoon, everybody. Welcome to the 42nd Annual JP Morgan Healthcare Conference. My name's Dan D'Arrigo, one of the associates on the healthcare banking team here today. It's my pleasure to introduce the Summit Therapeutics team.

So with us today, we have Dr. McKee, then going to the CEO and President, Bob Duggan, Chairman and CEO, who will be handling the presentation at the end of the presentation, we'll be doing a Q&A, and we'll be passing around the mike for the Q&A portion. I have a few other members of the team join us at the front, including they've gone cars, the Chief Business and Strategy Officer, Manmeet Soni, Chief Operating Officer, Dr. Allen Yang, Chief Medical Officer. And then Michelle, you see of a key So Inc., one of the collaboration partners.

So with that, I'll turn it over to that because I'm going to thank you very much, Danielle.

Maky Zanganeh Summit Therapeutics Inc.;CEO;President

&

Thank you very much for the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot